The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: Preliminary study

Infection and Chemotherapy

Volumn 45, Issue 1, 2013, Pages 62-68

  Hwang, Ji Hee ^a   Lee, Ju Hyung ^a   Moon, Mi Kyoung ^a   Kim, Ju Sin ^a   Won, Kyoung Suk ^a   Lee, Chang Seop ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Arbekacin; MRSA; Skin and soft tissue infection; Vancomycin

Indexed keywords

HABEKACIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEOPLASM; NEPHROTOXICITY; RASH; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84879078152     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2013.45.1.62     Document Type: Article

References (26)

1. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33 (Suppl 2):S84-S93.
2. Wilson SE. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. Surg Infect 2001;2:25-35.
3. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44 (Suppl A):19-23.
4. Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002;43:303-9.
5. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57:7-13.
6. Chung GT, Cha JG, Han SY, Jang HS, Lee KM, Yoo JI, Yoo JS, Kim HB, Eun SH, Kim BS, Park O, Lee YS. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006. J Microbiol Biotechnol 2010;20:637-42.
7. Lee K, Lee MA, Lee CH, Lee J, Roh KH, Kim S, Kim JJ, Koh E, Yong D, Chong Y; KONSAR Group. Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007. Yonsei Med J 2010;51:901-11.
8. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
9. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002;56:657-75.
10. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericidal, morphological and postantibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1997;39:471-6.
11. Lee J, Kim CK, Roh KH, Lee H, Yum JH, Yong D, Lee K, Chong Y. In vitro activity of arbekacin against clinical isolates of Staphylococcus species and Gram-negative Bacilli. Korean J Lab Med 2007;27:292-7.
12. Wie SH, Kang JH, Huh DH, Lee DG, Kim SI, Kim YR, Choi JH, Kim JH, Yoo JH, Hur JK, Shin WS, Kang MW. Antimicrobial activities of arbekacin against clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus species. Korean J Infect Dis 2001;33:254-60.
13. Kim TH, Choo EJ, Lee MS, Kim NJ, Woo JH, Ryu J, Chang MS, Yum YK. Clinical efficacy and safety with arbekacin for methicillin-resistant Staphylococcus aureus (MRSA) infections. Korean J Med 2003;65:239-44.
14. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001;10:785-92.
15. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis 2012;31:1663-6.
16. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9:1065-78.
17. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6.
18. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-74.
19. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:3763-9.
20. Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillinresistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 2003;47:3768-73.
21. Hamilton-Miller JM, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillinresistant Staphylococcus aureus. J Antimicrob Chemother 1995;35:865-8.
22. Suzuki K. Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int 2003;45:301-6.
23. Kobayashi Y, Uchida H, Kawakami Y. Arbekacin. Int J Antimicrob Agents 1995;5:227-30.
24. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14.
25. Ryu JS, Woo JH, Kim KW, Kim TH, Kim YH. Efficacy of teicoplanin in gram-positive bacterial infection. Korean J Infect Dis 1992;24:183-9.
26. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285-92.